Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION After a site-change that invalidates stability claims, CMC comparability package for a site change is the working evidence for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT. Decide whether the 505(b)(2) bridge is legally and scientifically enough using only what CMC comparability package for a site change actually supports.

DECISION Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol, Pause the pathway, Escalate safety review, Hold using CMC comparability package for a site change after a site-change that invalidates stability claims. The question on that file is whether the 505(b)(2) bridge is legally and scientifically enough.

HYPOTHESES TO TEST 1. CMC comparability package for a site change reads as Proceed under protocol once a site-change that invalidates stability claims is lined up to the same Pharma & Life Sciences population. 2. CMC comparability package for a site change is closer to Pause the pathway after a site-change that invalidates stability claims; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in CMC comparability package for a site change for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT. 4. CMC comparability package for a site change is missing the fact labeling negotiator needs after a site-change that invalidates stability claims; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 2. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a site-change that invalidates stability claims. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against a site-change that invalidates stability claims and write the one fact that would move the 505(b)(2) bridge is for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after a site-change that invalidates stability claims). The follow-on Clinical and Evidence Strategy action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in CMC comparability package for a site change, then the action for labeling negotiator - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - What changes the 505(b)(2) bridge is if a site-change that invalidates stability claims is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others